Traws Pharma, Inc. - Common Stock TRAW 深 沪
已收盘 09-19 16:00:00 美东时间
2.03
-0.030
-1.46%
华盛通- 最 高2.094
- 今 开2.08
- 成交量 11.85万股
- 最 低 1.98
- 昨 收 2.06
- 总市值 1433.95万
- 52周最高 19.44
- 市盈率 静 --
- 换手率 1.68%
- 52周最低 0.97
- 委 比 -0.88%
- 总股本 706.38万
- 历史最高 1751062.50
- 量 比 0.84
- 振 幅 5.53%
- 历史最低 0.97
- 每 手 1
- 风险率 4.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Traws Pharma Receives HREC Approval To Initiate Phase 2 COVID Studies Of Ratutrelvir, A Ritonavir-Free Treatment, With Results Expected By Year-End 2025
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVIDSeparate single-arm trial
08-18 19:08
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Traws Pharma announced the launch of Phase 2 trials for ratutrelvir, a ritonavir-free COVID treatment, to compare its safety and efficacy with Paxlovid. The trials will assess disease rebound rates, Long COVID incidence, and safety in Paxlovid-ineligible patients. Top-line results are expected by year-end 2025. Ratutrelvir aims to overcome shortcomings of current treatments, including unfavorable drug interactions and limited efficacy, with once-...
08-18 11:00
Traws Pharma Q2 2025 GAAP EPS $(0.11) Up From $(20.52) YoY, Sales $2.733M Up From $57.000K YoY
Traws Pharma (NASDAQ:TRAW) reported quarterly losses of $(0.11) per share. This is a 99.46 percent increase over losses of $(20.52) per share from the same period last year. The company reported $2.733 million in sales
08-14 19:04
Earnings Scheduled For August 14, 2025
Companies Reporting Before The Bell • Sunlands Technology (NYSE:STG) is likely ...
08-14 16:32
Traws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Traws Pharma, a clinical-stage biopharmaceutical company focused on novel therapies for respiratory viral diseases, will host a conference call on August 14, 2025, at 8:30 AM ET to discuss Q2 2025 financial results and recent progress. The call will be accessible via telephone or webcast, with replay available later. Traws is advancing antiviral agents targeting bird flu, seasonal influenza, and COVID-19, including Tivoxavir marboxil and Ratutrel...
08-08 11:00
Traws Pharma Seeks FDA Guidance On TXM For Bird Flu; Submits Phase 2 Studies For TXM, Ratutrelvir In Flu And COVID
Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern HemisphereBriefing documents submitted to FDA for a Type D meeting request to continue
06-30 18:45
Traws Pharma advances antiviral pipeline with multiple regulatory submissions
Traws Pharma (NASDAQ:TRAW) on Monday announced multiple regulatory submissions related to its antiviral pipeline. Phase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined ...
06-30 18:44
Traws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Traws Pharma submitted Phase 2 protocols for tivoxavir marboxil (TXM) to evaluate its efficacy against seasonal and bird flu, and for ratutrelvir to assess its effectiveness in COVID-19 patients, including those ineligible for PAXLOVID®. Briefing materials were also submitted to the FDA for a Type D meeting to explore accelerated approval for TXM for bird flu. The company aims to advance its antiviral portfolio to address critical respiratory vir...
06-30 10:30
Why RH Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Shares of RH (NYSE:RH) rose sharply in today's pre-market trading as the compan...
06-13 17:08
